Table 4.
Associations between the H2 haplotype (rs8070723) and MSA subtypes
| Series/MSA subtype | N | MAF (%) |
OR (95% CI) | P-value |
|---|---|---|---|---|
| Controls | 1312 | 23.0 | 1.00 (reference) | N/A |
| Pathologically confirmed MSA-P patients | 51 | 29.4 | 1.38 (0.89, 2.13) | 0.15 |
| Pathologically confirmed MSA-C patients | 20 | 7.5 | 0.27 (0.08, 0.88) | 0.030 |
| Pathologically confirmed MSA-mixed patients | 56 | 8.9 | 0.33 (0.17, 0.64) | 0.001 |
| Pathologically confirmed MSA-P or MSA-Mixed patients | 107 | 18.7 | 0.77 (0.54, 1.10) | 0.15 |
| Pathologically confirmed MSA-C or MSA-Mixed patients | 76 | 8.6 | 0.32 (0.18, 0.56) | <0.0001 |
| Clinically diagnosed MSA-P patients | 52 | 25.0 | 1.11 (0.71, 1.73) | 0.66 |
| Clinically diagnosed MSA-C patients | 24 | 27.1 | 1.22 (0.65, 2.28) | 0.53 |
| Clinically diagnosed MSA-Mixed patients | 10 | 35.0 | N/A1 | N/A |
| Clinically diagnosed MSA-P or MSA-Mixed patients | 62 | 26.6 | 1.20 (0.80, 1.80) | 0.38 |
| Clinically diagnosed MSA-C or MSA-Mixed patients | 34 | 29.4 | 1.37 (0.81, 2.30) | 0.24 |
| All MSA-P patients | 103 | 27.2 | 1.23 (0.90, 1.70) | 0.19 |
| All MSA-C patients | 44 | 18.2 | 0.74 (0.43, 1.27) | 0.28 |
| All MSA-Mixed patients | 66 | 12.9 | 0.50 (0.30, 0.84) | 0.008 |
| All MSA-P or MSA-Mixed patients | 169 | 21.6 | 0.92 (0.70, 1.21) | 0.55 |
| All MSA-C or MSA-Mixed patients | 110 | 15.0 | 0.60 (0.41, 0.87) | 0.007 |
ORs, 95% CIs, and p-values result from logistic regression models adjusted for age (age at death in pathologically confirmed MSA patients and age at blood collection in clinically diagnosed MSA patients and controls) and gender. ORs correspond to each additional H2 allele.
1
Logistic regression analysis was not performed owing to the small number of clinically diagnosed MSA-mixed patients.
MSA=multiple system atrophy; MAF=minor allele frequency; OR=odds ratio; CI=confidence interval